The Food and Drug Administration issued a Refusal to File letter to Acorda Therapeutics Inc.'s (Nasdaq: ACOR) for its new drug application for inbrija. Shares of the biopharmaceutical plunged $6.25 to close at $19.45.
Acorda Therapeutics receives Refusal to File letter
August 29, 2017 at 17:02 PM EDT
